|
1
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Szabo G and Bala S: MicroRNAs in liver
disease. Nat Rev Gastroenterol Hepatol. 10:542–552. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mendell JT: MicroRNAs: Critical regulators
of development, cellular physiology and malignancy. Cell Cycle.
4:1179–1184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tu K, Zheng X, Dou C, Li C, Yang W, Yao Y
and Liu Q: MicroRNA-130b promotes cell aggressiveness by inhibiting
peroxisome proliferator-activated receptor gamma in human
hepatocellular carcinoma. Int J Mol Sci. 15:20486–20499. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ranade AR, Cherba D, Sridhar S, Richardson
P, Webb C, Paripati A, Bowles B and Weiss GJ: MicroRNA
92a-2*: A biomarker predictive for chemoresistance and
prognostic for survival in patients with small cell lung cancer. J
Thorac Oncol. 5:1273–1278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z,
Sun J, Tan FW, Ding DP, Xu XH, Zhou F, et al: microRNA-92a promotes
lymph node metastasis of human esophageal squamous cell carcinoma
via E-cadherin. J Biol Chem. 286:10725–10734. 2011. View Article : Google Scholar :
|
|
8
|
Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW,
Lee CW, Wong YN, Chan FK, Yu J and Sung JJ: Detection of miR-92a
and miR-21 in stool samples as potential screening biomarkers for
colorectal cancer and polyps. Gut. 61:739–745. 2012. View Article : Google Scholar
|
|
9
|
Nilsson S, Möller C, Jirström K, Lee A,
Busch S, Lamb R and Landberg G: Downregulation of miR-92a is
associated with aggressive breast cancer features and increased
tumour macrophage infiltration. PLoS One. 7:e360512012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohyagi-Hara C, Sawada K, Kamiura S, Tomita
Y, Isobe A, Hashimoto K, Kinose Y, Mabuchi S, Hisamatsu T,
Takahashi T, et al: miR-92a inhibits peritoneal dissemination of
ovarian cancer cells by inhibiting integrin α5 expression. Am J
Pathol. 182:1876–1889. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou C, Shen L, Mao L, Wang B, Li Y and Yu
H: miR-92a is upregulated in cervical cancer and promotes cell
proliferation and invasion by targeting FBXW7. Biochem Biophys Res
Commun. 458:63–69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ranji N, Sadeghizadeh M, Shokrgozar MA,
Bakhshandeh B, Karimipour M, Amanzadeh A and Azadmanesh K:
MiR-17-92 cluster: An apoptosis inducer or proliferation enhancer.
Mol Cell Biochem. 380:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin HY, Chiang CH and Hung WC: STAT3
upregulates miR-92a to inhibit RECK expression and to promote
invasiveness of lung cancer cells. Br J Cancer. 109:731–738. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ke TW, Wei PL, Yeh KT, Chen WT and Cheng
YW: MiR-92a Promotes Cell Metastasis of Colorectal Cancer Through
PTEN-Mediated PI3K/AKT Pathway. Ann Surg Oncol. 22:2649–2655. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY,
Zhang JF, Shen HB, Zhang CY and Zen K: Serum microRNA profiles
serve as novel biomarkers for HBV infection and diagnosis of
HBV-positive hepatocarcinoma. Cancer Res. 70:9798–9807. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shigoka M, Tsuchida A, Matsudo T, Nagakawa
Y, Saito H, Suzuki Y, Aoki T, Murakami Y, Toyoda H, Kumada T, et
al: Deregulation of miR-92a expression is implicated in
hepatocellular carcinoma development. Pathol Int. 60:351–357. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tu K, Zheng X, Zhou Z, Li C, Zhang J, Gao
J, Yao Y and Liu Q: Recombinant human adenovirus-p53 injection
induced apoptosis in hepatocellular carcinoma cell lines mediated
by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. PLoS One.
8:e685742013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C,
Yao Y and Liu Q: Fbxw7 is an independent prognostic marker and
induces apoptosis and growth arrest by regulating YAP abundance in
hepatocellular carcinoma. Mol Cancer. 13:1102014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tu K, Zheng X, Zan X, Han S, Yao Y and Liu
Q: Evaluation of Fbxw7 expression and its correlation with the
expression of c-Myc, cyclin E and p53 in human hepatocellular
carcinoma. Hepatol Res. 42:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Z, Tu K and Liu Q: Effects of
microRNA-30a on migration, invasion and prognosis of hepatocellular
carcinoma. FEBS Lett. 588:3089–3097. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lv XB, Zhang X, Deng L, Jiang L, Meng W,
Lu Z and Wang X: MiR-92a mediates AZD6244 induced apoptosis and
G1-phase arrest of lymphoma cells by targeting Bim. Cell Biol Int.
38:435–443. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li M, Guan X, Sun Y, Mi J, Shu X, Liu F
and Li C: miR-92a family and their target genes in tumorigenesis
and metastasis. Exp Cell Res. 323:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Welcker M, Orian A, Jin J, Grim JE, Harper
JW, Eisenman RN and Clurman BE: The Fbw7 tumor suppressor regulates
glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein
degradation. Proc Natl Acad Sci USA. 101:9085–9090. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koepp DM, Schaefer LK, Ye X, Keyomarsi K,
Chu C, Harper JW and Elledge SJ: Phosphorylation-dependent
ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase.
Science. 294:173–177. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grandori C, Cowley SM, James LP and
Eisenman RN: The Myc/Max/Mad network and the transcriptional
control of cell behavior. Annu Rev Cell Dev Biol. 16:653–699. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hwang HC and Clurman BE: Cyclin E in
normal and neoplastic cell cycles. Oncogene. 24:2776–2786. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ohtsubo M, Theodoras AM, Schumacher J,
Roberts JM and Pagano M: Human cyclin E, a nuclear protein
essential for the G1-to-S phase transition. Mol Cell Biol.
15:2612–2624. 1995.PubMed/NCBI
|
|
28
|
Prendergast GC: Mechanisms of apoptosis by
c-Myc. Oncogene. 18:2967–2987. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sargent LM, Zhou X, Keck CL, Sanderson ND,
Zimonjic DB, Popescu NC and Thorgeirsson SS: Nonrandom cytogenetic
alterations in hepatocellular carcinoma from transgenic mice
overexpressing c-Myc and transforming growth factor-alpha in the
liver. Am J Pathol. 154:1047–1055. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li K, Lin SY, Brunicardi FC and Seu P: Use
of RNA interference to target cyclin E-overexpressing
hepatocellular carcinoma. Cancer Res. 63:3593–3597. 2003.PubMed/NCBI
|
|
31
|
Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST,
Chen J, Poon RT, Zender L, Lowe SW, Hong W, et al: AXL receptor
kinase is a mediator of YAP-dependent oncogenic functions in
hepatocellular carcinoma. Oncogene. 30:1229–1240. 2011. View Article : Google Scholar
|
